NCT00795847

Morning Hypertension and Preminent Therapy Study

The Efficacy and Safety of Losartan/Hydrochlorothiazide Combination Drug (Preminent) in Patients With Morning Hypertension

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 216 (actual)
• Sponsor: Kurume University · Academic / Other
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

It is difficult to control morning hypertension in practical clinical situation. Angiotensin receptor blocker (ARB) and thiazide are suggested to be effective to maintain the antihypertensive effects for 24 hours. However, monotherapy sometimes is not enough to control blood pressure level in the next morning and there are little evidence of the combination therapy for morning hypertension. The investigators hypothesized that a losartan 50 mg/hydrochlorothiazide 12.5 mg combination drug, Preminent, is effective and safe for controling morning hypertension, compared with high-dose of losartan 100 mg, in Japanese. Patients with morning hypertension were randomized to preminent treatment group or high-dose losartan treatment group. The efficacy and safety were compared after 3-month treatment.

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	Preminent (losartan/hydrochlorothiazide combination drug)	Preminent 1T qd (Arm 1) or losartan 100 mg (Arm 2) was given for 3 months.

Timeline

• Start date: 2008-11-01
• Primary completion: 2010-11-01
• Completion: 2010-11-01
• First posted: 2008-11-21
• Last updated: 2011-06-23

Locations

1 site across 1 country: Japan